Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ascendis Pharma A/S is a biotechnology business based in the US. Ascendis Pharma A/S shares (ASND) are listed on the NASDAQ and all prices are listed in US Dollars. Ascendis Pharma A/S employs 482 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $107.97 |
|---|---|
| 52-week range | $109.36 - $178.71 |
| 50-day moving average | $139.69 |
| 200-day moving average | $138.86 |
| Wall St. target price | $192.11 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-8.81 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $107.97 from 2022-01-21
| 1 week (2022-01-14) | -12.19% |
|---|---|
| 1 month (2021-12-22) | -22.34% |
| 3 months (2021-10-22) | -25.34% |
| 6 months (2021-07-22) | -7.99% |
| 1 year (2021-01-22) | -32.80% |
|---|---|
| 2 years (2020-01-22) | -19.18% |
| 3 years (2019-01-22) | 46.60% |
| 5 years (2017-01-20) | 408.57% |
| Revenue TTM | $3.4 million |
|---|---|
| Gross profit TTM | $7 million |
| Return on assets TTM | -24.14% |
| Return on equity TTM | -42.82% |
| Profit margin | 0% |
| Book value | $17.47 |
| Market capitalisation | $7 billion |
TTM: trailing 12 months
We're not expecting Ascendis Pharma A/S to pay a dividend over the next 12 months.
Over the last 12 months, Ascendis Pharma A/S's shares have ranged in value from as little as $109.36 up to $178.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ascendis Pharma A/S's is 0.7167. This would suggest that Ascendis Pharma A/S's shares are less volatile than average (for this exchange).
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. .
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.